Compare KOD & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOD | SRV |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 188.0M |
| IPO Year | 2018 | 2007 |
| Metric | KOD | SRV |
|---|---|---|
| Price | $37.52 | $45.88 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $31.14 | N/A |
| AVG Volume (30 Days) | ★ 948.6K | 58.9K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $34.24 |
| 52 Week High | $40.46 | $46.43 |
| Indicator | KOD | SRV |
|---|---|---|
| Relative Strength Index (RSI) | 72.45 | 64.63 |
| Support Level | $22.10 | $42.39 |
| Resistance Level | N/A | $46.41 |
| Average True Range (ATR) | 2.40 | 0.91 |
| MACD | 1.45 | 0.05 |
| Stochastic Oscillator | 67.44 | 84.77 |
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.